Castle Biosciences study finds 83% of atopic dermatitis patients interested in molecular testing to guide systemic therapy choice
CSTL•Castle Biosciences highlighted a published patient-and-caregiver study in which 83% of atopic dermatitis patients were interested in molecular testing to help choose systemic therapy.
1. Interest in testing
Castle Biosciences highlighted a newly published patient-and-caregiver study on atopic dermatitis treatment selection. Survey responses pointed to frequent therapy changes tied to unmet treatment goals, and most respondents expressed strong interest in molecular testing to help choose a systemic therapy.
Related News
Indonesia Energy management commentary says H1 2026 revenue rises 66.38% on higher Kruh Block output and $86.09/bbl crude price
INDO•
BP eyes Devon Energy asset amid renewed US M&A ambitions, sources say
BP•
